ADARx Targets $100 Million Biotech IPO

ADARx Pharmaceuticals, a clinical-stage biotechnology company developing small interfering RNA (siRNA) therapies, has filed with the Securities and Exchange Commission to raise up to $100 million in an initial public offering.

The San Diego-based company is developing next-generation siRNA therapeutics intended to address a broad range of diseases. ADARx plans to list on the Nasdaq under the symbol ADRX, although the company has not yet disclosed pricing terms for the offering.

Three Clinical-Stage Programs Lead the Pipeline

ADARx’s pipeline includes three clinical-stage programs and two advanced preclinical programs. Its three clinical-stage candidates target hepatic tissues and are being evaluated across complement-mediated diseases, hereditary angioedema and thrombotic diseases.

The company’s remaining two programs are in, or advancing toward, the IND-enabling stage. These candidates are being developed for obesity and neurodegenerative diseases, including Alzheimer’s disease.

The pipeline gives ADARx exposure to multiple therapeutic areas while maintaining a common focus on siRNA-based drug development.

Collaboration Revenue Reaches $6 Million

Founded in 2019, ADARx generated approximately $6 million in collaboration revenue for the 12 months ended June 30, 2026.

Unlike a commercial-stage pharmaceutical company with established product sales, ADARx remains primarily focused on advancing its clinical and preclinical pipeline. The company’s ability to progress its candidates through clinical development will therefore remain a key consideration for prospective public-market investors.

Major Banks Join the Offering

The proposed IPO has attracted several major investment banks. J.P. Morgan, Morgan Stanley, TD Cowen, UBS Investment Bank and LifeSci Capital are serving as joint bookrunners.

No pricing range, share count or final valuation was disclosed in the filing information provided, leaving the ultimate size and valuation of the offering subject to the company’s future IPO terms.

siRNA Platform Offers Multiple Development Opportunities

ADARx’s strategy centers on using siRNA therapeutics to target disease-related biological pathways. Its current programs span complement-mediated diseases, hereditary angioedema, thrombotic diseases, obesity and neurodegenerative conditions.

With three clinical-stage candidates and additional programs approaching IND-enabling studies, the company is building a pipeline that could provide several potential development opportunities if its candidates demonstrate sufficient safety and efficacy.

AD RX Moves Toward the Public Markets

ADARx Pharmaceuticals is entering the IPO market with a proposed $100 million fundraising target and a pipeline spanning multiple disease categories. Its $6 million in recent collaboration revenue remains modest relative to the proposed offering, underscoring the importance of clinical progress to the company’s future prospects.

As ADARx moves toward a Nasdaq listing under ADRX, investors will be watching for the company’s eventual pricing terms and additional details surrounding its clinical programs. The IPO would provide the biotechnology company with access to public-market capital as it advances its siRNA candidates through clinical development.